BioCentury | May 18, 2015
Emerging Company Profile

RIG-ged against cancer

...HBV and HCV. The company plans to begin Phase II trials this year for HBV. MultiCell Technologies...
...induced with helicase C domain 1 ; IFIH1 ) and RIG-I. Companies and Institutions Mentioned MultiCell Technologies Inc....
BioCentury | Mar 30, 2015
Company News

MultiCell Technologies Inc, Oxis deal

...for up to $12.8 million in clinical milestones and a 3% royalty on product sales. MultiCell Technologies...
BioCentury | Aug 12, 2013
Company News

Genisphere, MultiCell Technologies deal

...and gene construct therapeutics with improved efficacy and reduced toxicity. Genisphere LLC , Hatfield, Pa. MultiCell Technologies Inc....
BioCentury | Aug 20, 2012
Clinical News

MultiCell Technologies preclinical data

...IL-6 expression. MCT-485 a low molecular weight synthetic double-stranded RNA with direct tumor cytolytic properties. MultiCell Technologies Inc....
BioCentury | Aug 20, 2012
Clinical News

MultiCell Technologies preclinical data

...IFIH1 ; MDA5 ) and DEAD box polypeptide 58 ( DDX58 ; RIG-I ). MultiCell Technologies Inc....
BioCentury | Feb 27, 2012
Company News

MultiCell Technologies, Rutgers University deal

...believes the IP will apply to its coated cardiac stent business. Details were not disclosed. MultiCell Technologies Inc....
BioCentury | May 4, 2009
Product Development

Adjuvant Technologies

...and oligodeoxynocleotide ODN1a Juvaris BioTherapeutics Inc. JVRS-100 cationic lipid-DNA complex Molecular Express Inc. Lipsomal adjuvant MultiCell Technologies Inc....
BioCentury | Jan 7, 2008
Company News

MultiCell Technologies management update

MultiCell Technologies Inc. (OTCBB:MCET), Lincoln, R.I. Business: Neurology, Metabolic, Endocrine Resigned: Stephen Chang as president and CEO, while remaining a director and SAB member; Chairman W. Gerald Newmin will serve as interim president and CEO...
BioCentury | Oct 15, 2007
Company News

MultiCell Technologies, Corning Inc. deal

...to use Fa2N-4 and other cell lines to further develop its Sybiol liver assist device. MultiCell Technologies Inc....
BioCentury | Apr 30, 2007
Company News

MultiCell Technologies, Eisai deal

...under a three-year sub-license agreement with Nosan Corp. (Yokohama, Japan) (see BioCentury, Oct. 25, 2004). MultiCell Technologies Inc....
Items per page:
1 - 10 of 25
BioCentury | May 18, 2015
Emerging Company Profile

RIG-ged against cancer

...HBV and HCV. The company plans to begin Phase II trials this year for HBV. MultiCell Technologies...
...induced with helicase C domain 1 ; IFIH1 ) and RIG-I. Companies and Institutions Mentioned MultiCell Technologies Inc....
BioCentury | Mar 30, 2015
Company News

MultiCell Technologies Inc, Oxis deal

...for up to $12.8 million in clinical milestones and a 3% royalty on product sales. MultiCell Technologies...
BioCentury | Aug 12, 2013
Company News

Genisphere, MultiCell Technologies deal

...and gene construct therapeutics with improved efficacy and reduced toxicity. Genisphere LLC , Hatfield, Pa. MultiCell Technologies Inc....
BioCentury | Aug 20, 2012
Clinical News

MultiCell Technologies preclinical data

...IL-6 expression. MCT-485 a low molecular weight synthetic double-stranded RNA with direct tumor cytolytic properties. MultiCell Technologies Inc....
BioCentury | Aug 20, 2012
Clinical News

MultiCell Technologies preclinical data

...IFIH1 ; MDA5 ) and DEAD box polypeptide 58 ( DDX58 ; RIG-I ). MultiCell Technologies Inc....
BioCentury | Feb 27, 2012
Company News

MultiCell Technologies, Rutgers University deal

...believes the IP will apply to its coated cardiac stent business. Details were not disclosed. MultiCell Technologies Inc....
BioCentury | May 4, 2009
Product Development

Adjuvant Technologies

...and oligodeoxynocleotide ODN1a Juvaris BioTherapeutics Inc. JVRS-100 cationic lipid-DNA complex Molecular Express Inc. Lipsomal adjuvant MultiCell Technologies Inc....
BioCentury | Jan 7, 2008
Company News

MultiCell Technologies management update

MultiCell Technologies Inc. (OTCBB:MCET), Lincoln, R.I. Business: Neurology, Metabolic, Endocrine Resigned: Stephen Chang as president and CEO, while remaining a director and SAB member; Chairman W. Gerald Newmin will serve as interim president and CEO...
BioCentury | Oct 15, 2007
Company News

MultiCell Technologies, Corning Inc. deal

...to use Fa2N-4 and other cell lines to further develop its Sybiol liver assist device. MultiCell Technologies Inc....
BioCentury | Apr 30, 2007
Company News

MultiCell Technologies, Eisai deal

...under a three-year sub-license agreement with Nosan Corp. (Yokohama, Japan) (see BioCentury, Oct. 25, 2004). MultiCell Technologies Inc....
Items per page:
1 - 10 of 25